Oct. 21 at 7:00 PM
$CTXR $CTOR Recap of today's presentation. Interestingly, Leonard did not give the presentation. This was Paul Sowyrda, VP of Business Development & Market Intelligence.
LYMPHIR
• During the Q&A, he stated that they were planning to launch LYMPHIR by the end of the month
• In process of signing additional international agreements for LYMPHIR, plan to cover 38 countries by EoY. Price of drug in US is expected to be
$326,000 per patient per year
• Expect year initial sales to be under
$100M in first 12 months, profitable within first 9 months. Year 4 sales expected to be
$400M
• Trial combining LYMPHIR with KEYTRUDA: seeing 40% ORR in in-stage GYN cancers & they are in mature discusssions with Merck
• Trial combining LYMPHIR with CAR-T: seeing 91% resposne rates in refractory B-cell lymphomas
• CTOR has 18 months of LYMPHIR in inventory. CTOR raised
$9M last month, will be doing another raise in the next few weeks to support the commercial launch
More in comments